Individualization of antiretroviral therapy

Pharmacogenomics and Personalized Medicine

Volumn 5, Issue 1, 2011, Pages 1-17

  Pavlos, Rebecca ^a   Phillips, Elizabeth J ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

Antiretroviral; HIV; Personalized medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; GLYCOPROTEIN P; HLA B ANTIGEN; HLA DRB1 ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MARAVIROC; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; ORGANIC ANION TRANSPORTER 1; RALTEGRAVIR; SAQUINAVIR; UNINDEXED DRUG;

ALLELE; ANXIETY; AREA UNDER THE CURVE; CLINICAL PRACTICE; COMORBIDITY; DELAYED HYPERSENSITIVITY; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ENVIRONMENTAL FACTOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; INDIVIDUALIZATION; KIDNEY DISEASE; LIPOATROPHY; MAJOR DEPRESSION; PATIENT CARE; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PREDICTIVE VALUE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TREATMENT RESPONSE; VIVID DREAM;

EID: 84856809606     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S15303     Document Type: Review

References (154)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011:1-66. Available from: http://www.aidsinfo.nih.gov/ContentFiles/Adultand-AdolescentGL.pdf. Accessed September 4, 2011.
2. Thompson M, Aberg J, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333.
3. European AIDS Clinical Society Guidelines. Clinical Management and treatment of HIV-infected Adults in Europe. Version 5-4 2009. Available from: www.eacs.eu. Accessed October 17, 2011.
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 Revision. Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed October 17, 2011.
5. Swenson MC, Moores A, Low AJ, et al. Improved detection of CXCR4- using HIV by V3 genotyping: application of population based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr. 2010;54(5):506-510.
6. Parra J, Portilla J, Pulido F, et al. Clinical utility of maraviroc. Clin Drug Investig. 2011;31(8):527-542.
7. Phillips E, Mallal S. Personalizing antiretroviral therapy: is it a reality? Personalized Medicine. 2009;6(4):393-408.
8. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308): 727-732.
9. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variation in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121-1122.
10. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13(1):1-9.
11. Figueroa SC, de Gatta MF, Garcia LH, et al. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Ther Drug Monit. 2010;32(5):579-585.
12. Marzolini C, Telenti A, Decosterd LA, Greub G, Bioliaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 2001;15(1):71-75.
13. Arab-alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1 infected individuals. Clin Pharmcol Ther. 2009;85(5):485-494.
14. Di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogen Genomics. 2009;19(4):300-309.
15. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6(c.516 G--.T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol. 2009;67(4):427-436.
16. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS. 2009;23(16):2101-2106.
17. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylaiton. Drug Metab Dispos. 2010;38(7):1218-1229.
18. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glururonidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009;37(9):1793-1796.
19. Desta A, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007;8(6):547-558.
20. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of Cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450 reductase complex. J Pharmacol Exp Ther. 2001;338(3):803-809.
21. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G--.T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357-365.
22. Mehlotra RK, Bockarie MJ, Zimmerman PA. CYP2B6 983T.C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol. 2007;64(3):391-395.
23. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Metab Drug Metab Toxicol. 2010;6(1): 95-103.
24. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and *26. Clin Infect Dis. 2007;45(9):1230-1237.
25. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010;202(5):717-722.
26. Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1 infected patients. Pharmacogenomics. 2010;11(9):1223-1234.
27. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61(4):914-918.
28. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 2007;8(2):86-91.
29. Leger P, Dillingham R, Beauhamais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Portau-Prince, Haiti. J Infect Dis. 2009;200(6):955-964.
30. Mahungu T, Smith C, Turner F, et al. Cytochrome P450 2B6 516G--.T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 2009;10(5):310-317.
31. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007;21(16):2191-2199.
32. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42(3):401-407.
33. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous sytem side effects: an Adult AIDS Clinical Trials Group Study. AIDS. 2004;18(18):2391-4000.
34. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodefiency virus-infected patients in South India. Antimicrob Agents Chemother. 2009;53(3):863-868.
35. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogent Genomics. 2005;15(1):1-5.
36. Ramachandran G, Ramesh K, Hemanth Kumar AK, et al. Association of high T allele frequence of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother. 2009;63(4):841-843.
37. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6*6(Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenzcontaining regimens. Biochem Biophys Res Commun. 2004;319(4): 1322-1326.
38. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis. 2009;199(6): 872-880.
39. Chen J, Sun J, Ma Q, et al. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIVinfected patients. Ther Drug Monit. 2010;32(5):573-578.
40. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenetic Genomics. 2006;16(3):191-198.
41. Mukonzo JK, Roshammar D, Waako P, et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009;68(5):690-696.
42. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIVinfected individuals. Clin Pharmacol Ther. 2007;81(4):557-566.
43. Rotger M, Saumoy M, Zhang K, et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics. 2007;17(10):885-890.
44. Carr DF, la Porte CJ, Mirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother. 2010;65(9):1889-1893.
45. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of longterm responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005;192(11):1931-1942.
46. Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogent Genomics. 2006;16(11):837-845.
47. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;259(9300):30-36.
48. Rekic D, Roshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol. 2011;71(4):536-543.
49. Kawara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis co-infected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS. 2011;25(3):388-390.
50. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13-33.
51. Zhu D, Taguchi-Nakamura H, Goto M, et al. Influence of singlenucleotide polymorphisms in the multidrug resistance-1 gene on the cellular exposure of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther. 2004;9(6):929-935.
52. Winzer R, Langmann P, Zilly M, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res. 2003;8(12): 531-534.
53. Brumme ZL, Dong WW, Chan KJ, et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS. 2003;17(2):201-208.
54. Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother. 2010;44:157-165.
55. Lubomirov R, Rotger M, Fayet A, et al. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals [abstract]. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA; 2011:479.
56. Siccardi M, D'Avolio A, Baietto L, et al. Association of a singlenucleotide polymorphism in the pregnane X receptor (PXR 63396 C.T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis. 2008;47(9):1222-1225.
57. Shipani A, Siccardi M, D'Avolio A, et al. Population pharmacokinetic modelling of the association between 63396 C.T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010;54(12):5242-5250.
58. Svard J, Spiers JP, Mulcahy F, Hennessy M. Nuclear Receptor-Mediated Induction of CYP450 by Antiretrovirals: Functional Consequences of N1I2(PXR) Polymorphisms and Differential Prevalence in Whites and Sub-Saharan Africans. J Acquir Immune Defic Syndr. 2010;55(5):536-549.
59. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010;20(2):112-120.
60. Kohlrausch FB, de Cassia Estrela R, Barroso PF, Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentrations of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol. 2010;69(1):95-98.
61. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir co-formulated with ritonavir. Pharmacogenet Genomics. 2010;20(4):217-230.
62. Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85(6):623-627.
63. Fakenheuer G, Nelson M, Lazzarin A, et al. Subgroup analysis of maraviroc in previously treated R5 HIV-1 infection. N Eng J Med. 2008;359(14):1442-1455.
64. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24(4):565-573.
65. Peyieere H, Nicolas J, Siffert M, et al. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother. 2001;35(10): 1291-1292.
66. Hughes AR, Mosteller N, Bansal AT, et al. Association of genetic variation in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5(2):203-211.
67. Dejesus E, Herreera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviralnaive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038-1046.
68. Guilick R, Ribaudo H, Shikuma CM, et al. Three-versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296(7):769-781.
69. Dart Trial Team. Twenty-four week safety and tolerability of nevirapine vs abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health. 2008;13(1):6-16.
70. Hernandez J, Cutrell A, Bonny T, et al. Diagnosis of abacavir hypersensitivity reactions among patients receiving abacavir in two blinded studies. Antivir Ther. 2003;8:L88.
71. Phillips EJ, Sullivan JR, Knowles R, Shear NH. Utility of patch testing in patients with hypersensitivity reaction associated with abacavir. AIDS. 2002;16(16):2223-2225.
72. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19(9):979-981.
73. Shear NH, Milipied B, Bruynzeel DP, Phillips E. A review of drug patch testing and implications for HIV clinicians. AIDS. 2008;22(9): 999-1007.
74. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.
75. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunogenetically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111-1118.
76. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99-102.
77. Zucman D, Truchis P, Majerholc C, et al. Prospective genetic screening for human leuckocyte antigen-B*5701 avoid abacavir hypersensitivity in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr. 2007;45(1):1-3.
78. Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions. Antiviral Ther. 2006;11:L11.
79. Trottier B, Thomas R, Nguyen VK, Machouf N. How effectively HLA screening can reduce the early discontinuation of abacavir in real life [abstract]. Presented at the International AIDS Society Meeting. July 22-25, 2007; Sydney, Australia; 2007:MOPEB002.
80. Lalonde RG, Thomas R, Rachlis A, et al. Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens. 2009;75(1):12-18.
81. Waters LJ, Mandalia S, Gazzard B, et al. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS. 2007;21(18):2533-2534.
82. Young B, Squires K, Patel P, et al. First large multicentre open-label study utilizing HLA-B*5701screening for abacavir hypersensitivity in North America. AIDS. 2008;22(13):1673-1675.
83. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;101(12):4180-4185.
84. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;28(6):822-832.
85. Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequencespecific amplification: validation and comparison with sequence-based typing. Tissue Antigens. 2005;65(6):571-574.
86. Hammond E, Mamotte C, Nolan D, et al. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain melting assay. Tissue Antigens. 2007;70(1):58-61.
87. Martin AM, Krueger R, Almeida CA, et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics. 2006;16(5):353-357.
88. Dello Russo C, Lisi L, Lofaro A, et al. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*5701 detection by real-time PCR. Pharmacogenomics. 2011;12(4):567-576.
89. Kostenko L, Kjer-Nielsen L, Nicholson I, et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens. 2011;78(1):11-20.
90. Hammond E, Almeida CA, Mamotte C, et al. External quality assessment of HLA-B*5701 reporting and international multicentre survey. Antivir Ther. 2007;12(7):1027-1032.
91. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol. 2007;7(4):324-330.
92. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell counts. AIDS. 2005;19(1):97-99.
93. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20(12):1621-1626.
94. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21(2):264-265.
95. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogent Genomics. 2009;19(2):139-146.
96. Phillips E, Lucas M, Keane N, Lucas A, McKinnon E, Mallal S. HLA-B*35 is associated with nevirapine hypersensitivity in the contemporary Western Australian HIV cohort study. Eur Ann Allergy Clin Immunol. 2010;42:48.
97. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian and European descent. AIDS. 2011;25(10):1271-1280.
98. Haas DW, Bartlett JA, Anderson JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43(6):783-786.
99. Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006;43(6):779-782.
100. Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010;11(1):23-31.
101. Phillips E, Bartlett J, Sanne I, et al. Associations between HLADRB1* 0102, HLA-B*5801 and hepatotoxicity in patients who initiated nevirapine containing regimens in South Africa [abstract]. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 1, 2011; Boston, MA; 2011:949.
102. Vitezica ZG, Milipied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22(4):540-541.
103. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst. 2001;6(1):14-20.
104. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005;19(13):1341-1349.
105. Canter JA, Haas DW, Kallianpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J. 2008;8(1):71-77.
106. Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS. 2006;20(11):1503-1513.
107. Chew CS, Cherry CL, Imran D et al. Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients. Tissue Antigens. 2011;77(2):126-130.
108. Cherry CL, Rosenow A, Affandi JS, et al. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts and individuals NRTI-SN risk. AIDS Res Hum Retroviruses. 2008;24(2):117-123.
109. Afandi JS, Price P, Imran D, et al. Can we predict neuropathy risk before stavudine prescription in a resource-limited setting? AIDS Res Hum Retroviruses. 2008;24(1):1281-1284.
110. Yamanaka H, Gatanaga H, Kosalaraksa P, et al. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis. 2007;195(10):1419-1425.
111. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene 239G/A promoter polymorphism is associated with a more rapid onset of lipodystrophy. AIDS. 2003;17(1):121-123.
112. Maher B, Alfrevic A, Vilar FJ, et al. TNF-alpha promoter region gene polymoprhisms in HIV-positive patients with lipodystrophy. AIDS. 2003;16(15):2013-2018.
113. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, et al. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;51(2):111-116.
114. Hulgan T, Tebas P, Canter JA, et al. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis. 2008;197(6):858-866.
115. Asensi V, Rego C, Montes AH, et al. IL-1beta (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Gent Med. 2008;10(3):215-223.
116. Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008;22(13):1561-1568.
117. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, et al. Association between HLA-B*4001 and lipodystrophy among HIVinfected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin Infect Dis. 2010;50(4):597-604.
118. Nelson M, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273-1281.
119. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
120. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor based therapy. Journal of Inf Dis. 2008;197(1):102-108.
121. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. Clin Pharmacol Ther. 2008;83(2):265-272.
122. Izzedine H, Hulot JS, Villard E, et al. Association between ABBCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194(11):1481-1491.
123. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48(11): E108-E116.
124. Pushpakom SP, Liptrott NJ, Rodrigues-Novoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011;204(1):145-153.
125. Zucker SC, Qin X, Rouster SC. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A. 2001;98(22):12671-12676.
126. Solas C, Gagnieu MC, Ravaux I, et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit. 2008;30(6):670-673.
127. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor exposed patients. HIV Clin Trials. 2004;5(4):201-205.
128. Strassburg CP. Pharmacogenetics of Gilberts's syndrome. Pharmacogenomics. 2008;9(6):703-715.
129. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192(8):1381-1386.
130. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21(1):41-46.
131. Park WB, Choe PG, Song KH, et al. Genetic factors influencing severe atazanavir-associated hyperbilirbuinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis. 2010;51(1):101-106.
132. Kummer O, Mossdorf E, Battegay M, et al. Treatment of an atazanavir associated grade 4 hyperbilirubinemia with efavirenz. Gut. 2007;56(10):1477-1478.
133. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435 C--.T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42(2):291-295.
134. Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti HIV therapy: an observational cohort study. J Infect Dis. 2011;203(2):246-257.
135. Arnedo M, Tarffe P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics. 2007;17(9):755-764.
136. Rotger M, Bayard C, Taffe P, et al. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet. 2009;2(6):621-628.
137. Chang SY, Ko WS, Kao JT, et al. Association of single-nucleotide polymorphism 3 and c.553G. T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan. Clin Infect Dis. 2009;48(6):832-835.
138. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86(1):27-31.
139. Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapyassociated lipid disorders. J Infect Dis. 2005;191(9):1419-1426.
140. Tarr PE, Rotger M, Telenti A. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. Pharmacogenomics. 2010;11(4):587-594.
141. Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf. 2006;29(10):865-874.
142. Van Luiri M, Bannister WP, Mocroft A, et al. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther. 2009;14(1):75-83.
143. Wyen C, Hendra H, Siccardi M. Cytochrome P450 2B6(CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother. 2011;66(9):2092-2098.
144. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1 infected individuals. AIDS. 2003;17(8):1157-1165.
145. Demeter LM, Mukherjee AL, DiFrancesco R, et al. The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients. HIV Clin Trials. 2008;9(1):61-72.
146. Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010;54(4):381-388.
147. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43(15):1071-1087.
148. http://www.hiv-pharmacogenomics.org/pdf/ref_tbl_pharmaco/HIV_Pharmacogenomics_reference_table.pdf. Accessed October 11, 2011.
149. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2010;11(7):973-987.
150. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
151. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Gent. 2009;41(10): 1105-1109.
152. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(1):1100-1104.
153. Bachmann H, Siffert W, Skaletz-Rorowski A, et al. Impact of IL28B polymorphisms on sustained virologic response of HCV/HIV coinfected patients [abstract]. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections. 2011 Feb 27-Mar 1; Boston, MA; 2011:946.
154. Labarga P, Barreiro P, Mira JA, et al. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-co-infected patients with prior nonresponse or relapse. AIDS. 2011;25(8):1131-1133.